FENNEC PHARMACEUTICALS INC.FENCEarnings & Financial Report
Nasdaq · Health Care · Biological Products, (No Diagnostic Substances)
Fennec Pharmaceuticals Inc. is a biopharmaceutical firm focused on developing and commercializing therapies to reduce treatment-related side effects in pediatric cancer patients. Its lead product targets chemotherapy-induced ototoxicity, with core North American markets serving oncology providers and vulnerable pediatric patient groups.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| NOS. OF ABOVE PERSONS | 5.50% | 1.5M | ▲ +0.30pp | 2024-11-12 |
| Solas Capital Management, LLC | 5.20% | 1.4M | — | 2024-02-14 |
Insider Transactions
Net 90d: −$233.6K · buys $0 / sells $233.6KRange:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-04-01 | Rosty Raykov | Director | Option exercise | 15.6K | $2.45 | $38.2K |
| 2026-04-01 | Rosty Raykov | Director | Sell (open market) | 10.9K | $6.31 | $69.1K |
| 2026-03-31 | Evans Terry L | Chief Commercial Officer | Option exercise | 18.5K | $0.00 | $0 |
| 2026-03-31 | Evans Terry L | Chief Commercial Officer | Option exercise | 171 | $0.00 | $0 |
| 2026-03-31 | Robert Andrade | CHIEF FINANCIAL OFFICER | Option exercise | 14.7K | $0.00 | $0 |
| 2026-03-31 | Robert Andrade | CHIEF FINANCIAL OFFICER | Option exercise | 2.2K | $0.00 | $0 |
| 2026-03-31 | Hackman Jeffrey S. | Chief Executive Officer | Option exercise | 16.7K | $0.00 | $0 |
| 2026-03-31 | Hackman Jeffrey S. | Chief Executive Officer | Option exercise | 1.2K | $0.00 | $0 |
| 2026-03-31 | Sayad Pierre Sargis | Chief Medical Officer | Option exercise | 18.5K | $0.00 | $0 |
| 2026-03-31 | Sayad Pierre Sargis | Chief Medical Officer | Option exercise | 171 | $0.00 | $0 |
1–10 of 31
Page 1 / 4